Alnylam Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ALNY Alnylam Pharmaceuticals Inc
RHHBY Roche Holding AG
EGP Eastgroup Properties Inc
PMT PennyMac Mortgage Investment Trust
GS Goldman Sachs Group Inc
HLBZ Helbiz Inc
SRNE Sorrento Therapeutics Inc
OKTA Okta Inc
AAPL Apple Inc
CBTTF Cathedra Bitcoin Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Postmarket

Last Trade
Delayed
$124.96
-0.64 (-0.51%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$125.60
Day's Change
-1.15 (-0.91%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
129.06
Day's Low
125.02
Volume
(Light)
Volume:
330,301

10-day average volume:
838,866
330,301

Upcoming Events

ALNY's fiscal year ends in December
There are no upcoming events for ALNY

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
April 28, 2022Q1 2022 Earnings Release-$2.00-$2.14 to -$1.16-$1.71
February 10, 2022Q4 2021 Earnings Release-$2.16-$1.97 to -$1.12-$2.09
October 28, 2021Q3 2021 Earnings Release-$1.72-$2.01 to -$1.25-$2.18
August 3, 2021Q2 2021 Earnings Release-$1.61-$1.98 to -$1.14-$1.56

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.